Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors

Journal of Immunology

Volumn 172, Issue 12, 2004, Pages 7377-7384

  Matsumoto, Makoto ^a   Einhaus, Derek ^a   Gold, Elizabeth S ^a   Aderem, Alan ^a  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; LUCIFERASE; PROTEIN C FOS; PROTEIN C JUN; RNA; SIMVASTATIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ASSAY; GENETIC TRANSCRIPTION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

EID: 2942567910     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.12.7377     Document Type: Article

References (42)

1. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature 343:425.
2. Scandinavian Simvastatin Survival Study Group. 1994. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383.
3. Shepherd, J., S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop, and C. J. Packard. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1301.
4. Maron, D. J., S. Fazio, and M. F. Linton. 2000. Current perspectives on statins. Circulation 101:207.
5. Ridker, P. M., N. Rifai, M. A. Pfeffer, F. Sacks, and E. Braunwald. 1999. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230.
6. Keogh, A., P. Macdonald, A. Kaan, C. Aboyoun, P. Spratt, and J. Mundy. 2000. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J. Heart Lung Transplant. 19:529.
7. Kwak, B., F. Mulhaupt, S. Myit, and F. Mach. 2000. Statins as a newly recognized type of immunomodulator. Nat. Med. 6:1399.
8. Weitz-Schmidt, G., K. Welzenbach, V. Brinkmann, T. Kamata, J. Kallen, C. Bruns, S. Cottens, Y. Takada, and U. Hommel. 2001. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7:687.
9. Youssef, S., O. Stuve, J. C. Patarroyo, P. J. Ruiz, J. L. Radosevich, E. M. Hur, M. Bravo, D. J. Mitchell, R. A. Sobel, L. Steinman, and S. S. Zamvil. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78.
10. Aktas, O., S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, and F. Zipp. 2003. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197:725.
11. Montero, M. T., O. Hernandez, Y. Suarez, J. Matilla, A. J. Ferruelo, J. Martinez-Botas, D. Gomez-Coronado, and M. A. Lasuncion. 2000. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 153:303.
12. Sadeghi, M. M., M. Collinge, R. Pardi, and J. R. Bender. 2000. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J. Immunol. 165:2712.
13. Sun, D., and G. Fernandes. 2003. Lovastatin inhibits bone marrow-derived dendritic cell maturation and up-regulates proinflammatory cytokine production. Cell. Immunol. 223:52.
14. Monick, M. M., L. S. Powers, N. S. Butler, and G. W. Hunninghake. 2003. Inhibition of Rho family GTPases results in increased TNF-α production after lipopolysaccharide exposure. J. Immunol. 171:2625.
15. Liu, L., P. Moesner, N. L. Kovach, R. Bailey, A. D. Hamilton, S. M. Sebti, and J. M. Harlan. 1999. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J. Biol. Chem. 274:33334.
16. Krylov, D., M. Olive, and C. Vinson. 1995. Extending dimerization interfaces: the bZIP basic region can form a coiled coil. EMBO J. 14:5329.
17. Olive, M., D. Krylov, D. R. Echlin, K. Gardner, E. Taparowsky, and C. Vinson. 1997. A dominant negative to activation protein-1 (AP1) that abolishes DNA binding and inhibits oncogenesis. J. Biol. Chem. 272:18586.
18. Sonnenberg, J. L., F. J. Rauscher III, J. I. Morgan, and T. Curran. 1989. Regulation of proenkephalin by Fos and Jun. Science 246:1622.
19. Okada, S., S. Obata, M. Hatano, and T. Tokuhisa. 2003. Dominant-negative effect of the c-fos family gene products on inducible NO synthase expression in macrophages. Int. Immunol. 15:1275.
20. Smith, M., Z. Burke, A. Humphries, T. Wells, D. Klein, D. Carter, and R. Baler. 2001. Tissue-specific transgenic knockdown of Fos-related antigen 2 (Fra-2) expression mediated by dominant negative Fra-2. Mol. Cell. Biol. 21:3704.
21. Bohuslav, J., V. V. Kravchenko, G. C. Parry, J. H. Erlich, S. Gerondakis, N. Mackman, and R. J. Ulevitch. 1998. Regulation of an essential innate immune response by the p50 subunit of NF-κB. J. Clin. Invest. 102:1645.
22. Schindler, U., and V. R. Baichwal. 1994. Three NF-κB binding sites in the human E-selectin gene required for maximal tumor necrosis factor α-induced expression. Mol. Cell. Biol. 14:5820.
23. Hume, D. A., D. M. Underhill, M. J. Sweet, A. O. Ozinsky, F. Y. Liew, and A. Aderem. 2001. Macrophages exposed continuously to lipopolysaccharide and other agonists that act via Toll-like receptors exhibit a sustained and additive activation state. BMC Immunol. 2:11.
24. Gantner, B. N., R. M. Simmons, S. J. Canavera, S. Akira, and D. M. Underhill. 2003. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 197:1107.
25. Caivano, M., B. Gorgoni, P. Cohen, and V. Poli. 2001. The induction of cyclooxygenase-2 mRNA in macrophages is biphasic and requires both CCAAT enhancer-binding protein β (C/EBPβ) and C/EBP δ transcription factors. J. Biol. Chem. 276:48693.
26. Blank, J. L., P. Gerwins, E. M. Elliott, S. Sather, and G. L. Johnson. 1996. Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3: regulation of sequential phosphorylation pathways involving mitogen-activated protein kinase and c-Jun kinase. J. Biol. Chem. 271:5361.
27. Gri, G., D. Savio, G. Trinchieri, and X. Ma. 1998. Synergistic regulation of the human interleukin-12 p40 promoter by NFκB and Ets transcription factors in Epstein-Barr virus-transformed B cells and macrophages. J. Biol. Chem. 273:6431.
28. Murphy, T. L., M. G. Cleveland, P. Kulesza, J. Magram, and K. M. Murphy. 1995. Regulation of interleukin 12 p40 expression through an NF-κB half-site. Mol. Cell. Biol. 15:5258.
29. Plevy, S. E., J. H. Gemberling, S. Hsu, A. J. Domer, and S. T. Smale. 1997. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol. Cell. Biol. 17:4572.
30. Zhu, C., K. Gagnidze, J. H. Gemberling, and S. E. Plevy. 2001. Characterization of an activation protein-1-binding site in the murine interleukin-12 p40 promoter: demonstration of novel functional elements by a reductionist approach. J. Biol. Chem. 276:18519.
31. Bonny, C., A. Oberson, S. Negri, C. Sauser, and D. F. Schorderet. 2001. Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes 50:77.
32. Pope, R. M., A. Leutz, and S. A. Ness. 1994. C/EBP β regulation of the tumor necrosis factor a gene. J. Clin. Invest. 94:1449.
33. Zagariya, A., S. Mungre, R. Lovis, M. Birrer, S. Ness, B. Thimmapaya, and R. Pope. 1998. Tumor necrosis factor a gene regulation: enhancement of C/EBPβ-induced activation by c-Jun. Mol. Cell. Biol. 18:2815.
34. Liu, H., P. Sidiropoulos, G. Song, L. J. Pagliari, M. J. Birrer, B. Stein, J. Anrather, and R. M. Pope. 2000. TNF-α gene expression in macrophages: regulation by NF-κB is independent of c-Jun or C/EBP β. J. Immunol. 164:4277.
35. Kiener, P. A., P. M. Davis, J. L. Murray, S. Youssef, B. M. Rankin, and M. Kowala. 2001. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol. 1:105.
36. Smeal, T., P. Angel, J. Meek, and M. Karin. 1989. Different requirements for formation of Jun:Jun and Jun:Fos complexes. Genes Dev. 3:2091.
37. Li, L., J. C. Chambard, M. Karin, and E. N. Olson. 1992. Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression. Genes Dev. 6:676.
38. Kuchroo, V. K., A. C. Anderson, H. Waldner, M. Munder, E. Bettelli, and L. B. Nicholson. 2002. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 20:101.
39. Hoffmann, G. F., C. Charpentier, E. Mayatepek, I. Mancini, M. Leichsenring, K. M. Gibson, P. Divry, M. Hrebicek, W. Lehnert, K. Sartor, et al. 1993. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 91:915.
40. Houten, S. M., W. Kuis, M. Duran, T. J. de Koning, A. van Royen-Kerkhof, G. J. Romeijn, J. Frenkel, L. Dorland, M. M. de Barse, W. A. Huijbers, et al. 1999. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 22:175.
41. Drenth, J. P., L. Cuisset, G. Grateau, C. Vasseur, S. D. van de Velde-Visser, J. G. de Jong, J. S. Beckmann, J. W. van der Meer, and M. Delpech. 1999. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome: International Hyper-IgD Study Group. Nat. Genet. 22:178.
42. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133.